Comparative Pharmacology
Head-to-head clinical analysis: CHLORAMPHENICOL SODIUM SUCCINATE versus TRIMPEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORAMPHENICOL SODIUM SUCCINATE versus TRIMPEX.
CHLORAMPHENICOL SODIUM SUCCINATE vs TRIMPEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversibly binds to the 50S ribosomal subunit, inhibiting peptidyl transferase activity and blocking protein synthesis in bacteria.
Inhibits dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid, thereby inhibiting bacterial thymidine synthesis and DNA replication.
Intravenous, 50 mg/kg/day divided every 6 hours; maximum 4 g/day.
5 mg/kg orally every 6 hours for acute infections; 5 mg/kg orally every 12 hours for chronic urinary tract infections.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-3.5 hours in adults with normal renal and hepatic function. In neonates (first 2 weeks of life), half-life is prolonged to 10-24 hours due to immature hepatic conjugation. In patients with severe hepatic impairment, half-life may exceed 12 hours, necessitating dose adjustment.
8-11 hours; prolonged in renal impairment (creatinine clearance <10 mL/min: 20-40 hours)
Approximately 80-90% of the dose is excreted renally as unchanged drug and as the inactive chloramphenicol base (formed by hydrolysis in the liver and kidneys). Biliary excretion accounts for about 5-10%, with some enterohepatic circulation. Fecal excretion is negligible (<2%).
Renal: 40-70% as unchanged drug; biliary/fecal: minimal (10-15% as metabolites)
Category D/X
Category C
Antibiotic
Antibiotic